MHRA - UK approves Molnupiravir

[imhotep]

UK is the first country to approve Molnupiravir.

The antiviral Lagevrio (Molnupiravir) is safe and effective at reducing the risk of hospitalization and death in people with mild to moderate COVID-19 who are at increased risk of developing severe disease, the Medicines and Healthcare products Regulatory Agency (MHRA) announced today.

This follows a rigorous review of its safety, quality and effectiveness by the UK regulator and the government's independent expert scientific advisory body, the Commission on Human Medicines, making it the first oral antiviral for the treatment of COVID-19 to be approved.

Developed by Ridgeback Biotherapeutics and Merck Sharp & Dohme (MSD), Lagevrio works by interfering with the virus' replication. This prevents it from multiplying, keeping virus levels low in the body and therefore reducing the severity of the disease.

Based on the clinical trial data, Lagevrio is most effective when taken during the early stages of infection and so the MHRA recommends its use as soon as possible following a positive COVID-19 test and within five days of symptoms onset

Molnupiravir has been authorised for use in people who have mild to moderate COVID-19 and at least one risk factor for developing severe illness. Such risk factors include obesity, older age (>60 years), diabetes mellitus, or heart disease.

PS: There were several threads posted since it's development started and the most recent one
https://elakiri.com/threads/molnupiravir-the-oral-antiviral-for-covid-licensing-concerns.2015961/

 

[NRTG]

BUMP

 

[vipulavs]

Machanla oke side effect ekakuth thiyenavalu neda. Mokak hari replicate seen ekak. Mn dakka article ekaka thiyenava.

 

[imhotep]

Machanla oke side effect ekakuth thiyenavalu neda. Mokak hari replicate seen ekak. Mn dakka article ekaka thiyenava.

Please read my other thread on the link shown. Molnupiravir is an antiviral in the category of mutagenic ribonucleosides. It can change the viral genetic material and introduce errors to prevent replication and transcription of the viral genome. It's even capable to defeat the virus' proof reading mechansim to a certain extent. (Covid virus encode an RNA proofreading exoribonuclease (nsp14-ExoN) that is responsible for high-fidelity RNA synthesis.)

Inside the host cell, molnupiravir is converted to molnupiravir triphosphate. When the virus tries to replicate, molnupiravir triphosphate is incorporated into the viral RNA instead of the nucleoside cytidine, causing a mutation.

The mutation stops the virus from replicating keeping the virus counts low and thus lowering the disease severity. This causes concern that the drug might cause cancers or birth abnormalities. Tests have been done but none available in the public domain but certainly submitted to the authorities concerned.

 

[hodakolla]

BUMPER